特发性矮小症患儿rhGH治疗前后血清促酰化蛋白水平变化及与疗效的相关性分析  

Changes of serum acylation stimulating protein levels before and after rhGH treatment in children with idiopathic short stature and their correlation with curative effect

作　　者：相媛媛 杜维维 高世全 李学超 王建忠 XIANG Yuanyuan;DU Weiwei;GAO Shiquan;LI Xuechao;WANG Jianzhong(Department of Child Health,Qinhuangdao Maternal and Child Health Hospital,HeBei QianHuangDao 066000,China;Department of Pediatrics,Qinhuangdao Maternal and Child Health Hospital,HeBei QianHuangDao 066000,China)

机构地区：[1]秦皇岛市妇幼保健院儿保科,河北秦皇岛066000 [2]秦皇岛市妇幼保健院儿科,河北秦皇岛066000

出　　处：《中国妇幼健康研究》2023年第12期41-45,共5页Chinese Journal of Woman and Child Health Research

基　　金：秦皇岛市科学技术研究与发展计划(202301A220)。

摘　　要：目的探讨分析特发性矮小症患儿重组人生长激素(rhGH)治疗前后血清促酰化蛋白水平(ASP)变化及与疗效的相关性。方法选取2020年6月至2021年6月秦皇岛市妇幼保健院收治的124例特发性矮小症患儿作为观察组,予以rhGH治疗,并选取同期体检无异常的儿童80例作为对照组。收集研究对象入院时、治疗3个月后及治疗6个月后身高、体重和生长速率,并采用酶联免疫吸附法检测各时间点血清ASP水平、胰岛素样生长因子-1(IGF-1),分析治疗前后其水平变化及与rhGH治疗效果的关系。结果特发性矮小症患儿身高、生长速率、血清ASP、IGF-1水平均低于正常儿童(t值分别为5.901、34.128、15.076、11.790,P<0.05);治疗前、治疗3个月后、治疗6个月后患儿身高、血清ASP、IGF-1水平均依次增高,差异有统计学意义(F值分别为21.958、102.747、320.636,P<0.05);治疗6个月后特发性矮小症患儿身高增长和生长速率均高于治疗3个月(t值分别为26.320、4.019,P<0.05);Pearson相关性分析结果显示,治疗3个月后、治疗6个月后血清ASP水平与患儿身高、体重、生长速率均呈正相关关系(r值介于0.478~0.571之间,P<0.05);治疗6个月后,血清ASP与IGF-1呈正相关关系(r=0.413,P<0.05)。结论特发性矮小症患儿经rhGH治疗后血清ASP水平升高,其水平与患儿身高、体重、生长速率、IGF-1呈正相关关系,其水平变化与患儿生长发育密切相关,可为rhGH促生长治疗效果评估提供重要参考依据。Objective To investigate the changes of serum acylation stimulating protein(ASP)levels before and after recombinant human growth hormone(rhGH)treatment in children with idiopathic short stature,and the correlation with therapeutic efficacy.Methods A total of 124 children with idiopathic short stature admitted to Qinhuangdao Maternal and Child Health Hospital from June 2020 to June 2021 were selected as the observation group and treated with rhGH,and 80 children with no abnormal physical examination during the same period were selected as the control group.Height,weight and growth rate were collected from the study participants at admission,after 3 months of treatment and after 6 months of treatment,and serum ASP levels and insulin-like growth factor-1(IGF-1)were measured by enzyme-linked immunosorbent assay(ELISA)at each time point,to analyze the changes in their levels before and after the treatment,and their relationship with the therapeutic effect of rhGH.Results Children with idiopathic short stature had lower height,growth rate,serum ASP,and IGF-1 levels than normal children(t=5.901,34.128,15.076 and 11.790,respectively,P<0.05).The levels of height,ASP and IGF-1 in serum increased sequentially before treatment,after 3 months and after 6 months,and the differences were statistically significant(F=21.958,102.747 and 320.636,respectively,P<0.05).The height growth and growth rate of children with idiopathic short stature after 6 months of treatment were higher than those at 3 months of treatment(t=26.320 and 4.019,respectively,P<0.05).Pearson correlation analysis showed that serum ASP levels were positively correlated with children s height,weight,and growth rate after 3 months and 6 months of treatment(r=0.478-0.571,respectively,all P<0.05).After 6 months of treatment,serum ASP was positively correlated with IGF-1(r=0.413,P<0.05).Conclusion The serum ASP level of children with idiopathic short stature increased after rhGH treatment,and its level was positively correlated with the height,weight,growth rate and I

关 键 词：特发性矮小症 重组人生长激素 促酰化蛋白 生长发育 

分 类 号：R179[医药卫生—妇幼卫生保健]